NeonMind Strengthens its Specialty Clinics Advisory Board with Appointment of Mood Disorders and Ketamine Expert Dr.… Sep 22, 2021
DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder Sep 21, 2021
Small Pharma Successfully Completes Phase I Clinical Trial of DMT in Combination with Supportive Psychotherapy Sep 21, 2021
Mindset Pharma Announces Further Preclinical Results Demonstrating Strong Efficacy and Improved Safety Profile for its… Sep 20, 2021
Delic to Acquire Ketamine Wellness Centers Inc, Becoming Largest Psychedelic Wellness Chain in United States Sep 20, 2021
TerrAscend Receives Michigan Pre-Qualification Approval for the Acquisition of Gage Cannabis Sep 17, 2021
NeonMind Appoints Ketamine and Neurostimulation Expert Dr. Roumen Milev, MD, PhD to Specialty Clinic Advisory Board Sep 16, 2021
MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry Sep 16, 2021
